SYS6002, a subsidiary of CSPC Innovation (300765.SZ), announced research results at the 2026 International Society of Gynecological Oncology Global Annual Meeting

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”), announced the Phase I clinical study data of SYS6002 monotherapy for the treatment of advanced cervical cancer in the form of a quick oral report at the 2026 International Society of Gynecological Oncology Global Meeting (IGCS Annual Global Meeting) held in Montreal, Canada from October 1 to October 3.

SYS6002 is a next-generation antibody-conjugated drug (ADC) targeting nectin-4. The drug uses enzymatically catalyzed site-specific antibody conjugation technology to target the effective mitosis inhibitor MMAE on cancer cells expressing Nectin-4. Its stable connector design not only helps deliver high concentrations of MMAE to tumors, but also reduces toxicity by reducing the level of systemic exposure to the toxin.

The relevant safety and efficacy data are as follows: In terms of safety, the safety of the above two dosage groups is generally manageable, and most treatment-related adverse events are grade 1-2. Among them, ocular adverse events were the most common, but there were no grade 3 or above events, and none of the cases were discontinued as a result. The incidence of interstitial lung disease and non-infectious pneumonia is low (2.4%). The incidence and severity of treatment-related rashes were low (any grade: 20.7%; grade 3:1.2%), and no cases of Stevens Johnson syndrome or toxic epidermal necrolysis occurred. The incidence and severity of peripheral neuropathy is also low (12.2%; both grade 1-2). There were no treatment-related adverse events leading to death.

In terms of efficacy, both dosage regimens showed initial efficacy in the study population. The confirmed objective response rate for the 2.4 mg/kg dose group was 35.9%, and the confirmed objective response rate for the 3.6 mg/kg dose group every 3 weeks was 28.6%. The median duration of remission in the two groups of patients who achieved confirmed remission was 8.2 months and 10.3 months, respectively; the median progression-free survival was 4.1 months and 4.3 months, respectively; the median overall survival was 15.1 months and 11.5 months, respectively.